Exparel for Total Shoulder Pain

Launched by UNIVERSITY OF SOUTH FLORIDA · Nov 8, 2018

Keywords

ClinConnect Summary

This clinical trial is studying how effective a medication called Exparel (which is a type of local anesthetic) is at managing pain after total shoulder surgery compared to another medication called Ropivacaine. Total shoulder surgery is commonly done to relieve pain from arthritis, but many patients still experience significant pain afterward. This study aims to find out which medication better helps control post-surgery pain, as well as how they affect recovery time and overall patient satisfaction.

To participate in this trial, you need to be at least 18 years old and scheduled for total shoulder replacement surgery at TGH. You should also be able to give informed consent, meaning you understand the study and agree to take part. However, if you have allergies to Exparel or Ropivacaine, are pregnant, or have certain muscle disorders, you won't be eligible. If you join the study, you’ll receive one of the medications during your surgery, and the team will monitor your pain levels, any complications, and how long you stay in the hospital. Your participation could help improve pain management for future shoulder surgery patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 18 years or older
• • Patients admitted to TGH for total shoulder replacement surgery
• • Subjects who have given written informed consent
• Exclusion Criteria:
• • Patients with allergic reactions to Exparel or Ropivacaine
• • Female patients who are pregnant
• • Subjects known or suspected to have neuromuscular disorders impairing neuromuscular blockade (e.g., subjects with myasthenia gravis)